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Abstract RANTES (regulated upon activation normal T cell
expressed and secreted) is a chemoattractant cytokine important
in the generation of inflammatory responses and human
immunodeficiency virus resistance. In hematopoietic cells,
RANTES is over-expressed by type I interferons (IFN-K and
IFN-L). The upstream region of the RANTES gene promoter
contains a distal low affinity IFN-stimulated response element
(ISRE). Specific mutagenesis in this ISRE-like motif abolished
the activation of RANTES transcription by type I IFNs.
Examination of the ISRE binding factors strongly suggested
that signal transducer and activator of transcription (Stat)-2 and
p48/IFN-stimulated gene factor 3Q (ISGF3Q) are not required for
the induction of RANTES by type I IFNs. The specific
requirement of Stat-1 was demonstrated using Stat-1-deficient
U3A cells. These results revealed a non-classical ISRE/ISGF3
signal transduction pathway for the induction of RANTES by
type I IFNs. ß 2002 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Transcriptional responses to interferon (IFN) are mediated
by tyrosine phosphorylation of nuclear factors of the signal
transducer and activator of transcription (Stat) family [1]. The
Stat-1 and Stat-2 proteins, present in the cytoplasm of un-
treated cells, become rapidly activated through tyrosine phos-
phorylation by two receptors of the Janus kinase (Jak) family,
Jak1 and Tyk2, upon stimulation with type I IFNs (IFN-K
and IFN-L) [2,3]. This activation subsequently allows Stat-1
and Stat-2 to assemble together within IFN-stimulated gene
factor 3K (ISGF3K) [4]. This ISGF3K complex interacts with
the p48/ISGF3Q protein, which activates transcription of IFN-
stimulated genes through binding interactions with an IFN-
stimulated response element (ISRE) present in many pro-
moters activated by type I IFNs [2].
RANTES (regulated upon activation normal T cell ex-
pressed and secreted) is a basic 8-kDa polypeptide of the
CC-chemokine subfamily, produced by various cell types, in-
cluding CD8 T cells, CD4 T cells, and macrophages [5,6].
The functions of RANTES include attracting blood leuko-
cytes to the site of in£ammation, regulating leukocytes matu-
ration, tra⁄cking and homing, and the development of lym-
phoid tissues [6]. In addition, RANTES plays a pivotal role
during human immunode¢ciency virus (HIV) infection. This
chemokine highly expressed in some HIV-infected patients
that do not progress to AIDS inhibits HIV infection [7]. Pre-
viously, we have observed the induction of RANTES produc-
tion in several cell types (T lymphocytes, macrophages and
dendritic cells) that constitutively express an IFN-L transgene
[8^10]. In macrophages, the resistance against HIV, markedly
enhanced by IFN-L, was virtually suppressed by RANTES-
neutralizing antibody [9]. Similarly, in HIV-1-speci¢c CTL
cells, the induction of RANTES by IFN-L increased signi¢-
cantly the level of the speci¢c lysis via the HIV entry corecep-
tor CCR3, and this e¡ect is abolished in the presence of anti-
RANTES antibody [11,12].
Thus, understanding the molecular basis for control of
RANTES gene expression may help in the design and devel-
opment of novel immunotherapies for a variety of diseases. In
this study, we report that type I IFNs increase RANTES
mRNA transcription and we provide the ¢rst evidence that
RANTES gene is regulated in response to type I IFNs and
that it requires an ISRE-like sequence, through the signaling
protein Stat-1, in the absence of Stat-2 and p48/ISGF3Q pro-
teins.
2. Materials and methods
2.1. Nuclear run-on
HPB-ALL and CEM cells were cultured for 4 h in the presence of
IFN-K2 or IFN-L (1000 U/ml), and nuclei were harvested, as previ-
ously described [13]. Transcription initiated in intact cells was allowed
to complete in the presence of [K-32P]UTP, and the RNA was isolated
and hybridized to slot-blotted probe (1 Wg of DNA per slot) contain-
ing speci¢c cDNA [13].
2.2. DNA construct
A 602-bp and a 1016-bp 5P-non-coding fragment upstream of the
6-16 and RANTES genes, respectively, were isolated by PCR ampli-
¢cation of genomic DNA derived from HPB-ALL cells. These ampli-
¢ed fragments were cloned into the pXP-2 luciferase reporter plasmid
by using HindIII and KpnI restriction sites. The reporter plasmid
pvRANTES was constructed by inserting the ISRE-like element
(3672 to 3616) of RANTES gene promoter upstream of the minimal
sequence promoter of RANTES from 380 to +3. Punctual mutations
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in the ISRE-like element of the RANTES gene promoter were intro-
duced using the Site-Directed Mutagenesis kit (Clontech). All of the
constructions were veri¢ed by sequence analysis.
2.3. Transfection and luciferase assay
Forty million of CEM, Jurkat, HPB-ALL and U937 cells were
transiently transfected by electroporation using a Cellject electropo-
rator (Eurogentec), with 20 Wg of plasmid DNA. The electroporator
was set at 2100 WF capacitance, and 240 V. After electroporation, the
cells were resuspended in RPMI 1640 supplemented with 10% SVF.
2fTGH, U1A, U2A and U3A cells (kindly provided from I. Kerr,
Imperial Cancer Research Foundation, London, UK, and S. Pellegri-
ni, Institut Pasteur, Paris, France) were transfected using calcium
phosphate^DNA precipitates performed according to Bailly et al.
[14]. Two days after transfection, luciferase activity was assayed using
a Luciferase Assay System kit (Promega) and was measured in a
Berthold counter (CliniLumat). As control, the plasmid pEFBosLacZ
was cotransfected to normalize the transfection e⁄ciency. Galactosi-
dase activity was assayed using the Galacto-start kit (Tropix).
2.4. Mobility shift assay and supershift
Nuclear extracts were prepared as previously described [15]. For
binding reaction, nuclear extracts (10 Wg of protein) were incubated
in bu¡er containing 20 mM HEPES (pH 8), 0.1 mM EDTA, 1 mM
dithiothreitol, 5% glycerol, 0.2 mg/ml bovine serum albumin and 1 Wg
of poly-deoxyinosinic-deoxycytidylic acid, for 15 min at 4‡C. Double-
stranded oligonucleotides were prepared by annealing the complemen-
tary single strands and were radiolabeled using the Klenow fragment
of DNA polymerase I and [K-32P]dATP in a ¢ll-in reaction for 5P-
protruding ends. The following oligonucleotides were used: ISRE
from ISG15 gene promoter, as previously described [15]; ISRE-like
from RANTES gene promoter: 5P-gatcCTTTCTAAACAAGGAAA-
TAGAACTCAAAGACAT-3P and 3P-GAAATATTTGTTCCTTTA-
TCTTGAGTTTCTGTActag-5P ; mutant ISRE-like from RANTES
gene promoter: 5P-gatcCTTTCTAAACAAGGATATAGATCTCAA-
AGACAT-3P and 3P-GAAATATTTGTTCCATATCTAGAGTTTC-
TGTActag-5P ; GAS from ISGF2 gene promoter [16] : 5P-ctga-
TTTCCCCGAAAtgac-3P and 3P-gactAAAGGGGTTTactg-5P. The
32P-labeled oligonucleotide (0.1 pmol) was then added to the reaction
mixture and incubated for 30 min at room temperature. In some
experiments, antibodies against Stat-1K/p91, (kindly provided from
B. Williams, The Cleveland Clinic Foundation, OH, USA), Stat-2/
p113, Stat-3, Stat-5, ISGF3Q/p48, IRF-1, ICSBP and p300 (purchased
from Santa Cruz Biotechnology) were included in the reaction mix-
ture. The reaction products were analyzed by electrophoresis in a 5%
non-denaturing polyacrylamide gel with 0.25% TBE bu¡er. The gel
was dried and analyzed by autoradiography.
3. Results and discussion
Previously, we have shown that type I IFNs induced
RANTES production in various human hematopoietic cells
[9^12]. Therefore, we investigated whether up-regulation of
RANTES production by type I IFNs occurred at the tran-
scriptional level. The level of run-on transcripts was respec-
tively 40- and 80-fold higher in CEM and HPB-ALL cells,
respectively, after treatment with IFN-K or IFN-L, as com-
pared to untreated cells (Fig. 1), indicating that type I IFNs
induce the rate of RANTES gene transcription.
To analyze the e¡ect of type I IFNs on RANTES gene
promoter activity in several hematopoietic cell lines, HPB-
ALL, CEM, Jurkat and U937 cells were transiently trans-
fected with luciferase reporter constructs containing either
the 6-16 gene promoter (p6-16), as a positive control [17], or
the RANTES gene promoter (pRANTES). As shown in Fig.
2, the activity of the p6-16 gene promoter was induced more
than 30-fold following treatment with either IFN-K2 or IFN-
L, irrespective of the cell type analyzed. Similarly, the activity
of the RANTES promoter construct was induced 20^100-fold.
Furthermore, a dose^response curve of IFN-L suggested that
the induction of the RANTES gene promoter activity is cor-
related with the dose of type I IFNs (data not shown).
These results suggest the presence of a type I IFN-respon-
sive sequence in the RANTES gene promoter. Inspection of
this sequence reveals a motif, 5P-TTCTAAACAAGGAAA-
TAGAAC-3P at position 3653 relative to the ATG start co-
don, containing an ISRE-like element (Fig. 3A) [18]. Another
ISRE-like element was previously described in the RANTES
gene promoter, between nucleotides 3123 and 396 [19]. The
interaction of the IRF-3/IRF-7 factors with this proximal
ISRE-like motif induces speci¢cally RANTES production
after virus infection, in the absence of type I IFNs, indicating
that this proximal ISRE-like element is not implicated in the
direct induction of RANTES expression by type I IFNs
Fig. 1. Induction of RANTES gene transcription by IFN-K2 and
IFN-L. CEM and HPB-ALL cells were untreated or treated with
IFN-K2 (IFK) or IFN-L (IFL) at 1000 U/ml for 90 min. Nuclei
were harvested and transcriptional activity was assayed by nuclear
run-on analysis. 32P-labeled RNA transcripts were hybridized with
dot-blotted cDNA encoding RANTES or GAPDH, as indicated.
Similar results were obtained in two separate experiments.
Fig. 2. IFN-K2 and IFN-L up-regulate the RANTES gene promoter
activity. HPB-ALL, CEM, Jurkat and U937 cells were transiently
transfected with the indicated constructs (p6.16 or pRANTES) and
then treated with 1000 U/ml IFN-K2 (open bars) or IFN-L (closed
bars). Levels of luciferase activity, determined 24 h later, were ex-
pressed as fold induction relative to untreated cells. Results are
means þ S.D. of three independent experiments.
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[19,20]. To determine the speci¢c function of the distal ISRE-
like element in type I IFNs induction, we obtained a
RANTES gene promoter construct (pvRANTES) containing
only the distal ISRE-like element (3672 to 3616). This con-
struction was transfected in HPB-ALL cells, and the luciferase
activity was determined after IFN-L treatment. As shown in
Fig. 3B, this distal ISRE-like motif is su⁄cient to respond to
type I IFNs. Furthermore, two mutants of the ISRE-like el-
ement (mISRE1 and mISRE2) failed to respond to type I
IFNs stimulation (Fig. 3B). Taken together, these results in-
dicate that the integrity of this distal ISRE-like element is
critical and su⁄cient for the response of the RANTES gene
promoter to type I IFNs. Using a nucleotide alignment pro-
gram, any similar combination of ISRE-like motifs was iden-
ti¢ed in the gene promoter of the other chemokines induced
by type I IFNs; MIP-1K, MCP-1 or MCP-3 [21,22]. This
observation suggests the concept that chemokine genes may
be regulated by di¡erent mechanisms in response to type I
IFNs.
To demonstrate that transcription factors speci¢cally inter-
act with this ISRE-like element, electrophoretic mobility shift
assay (EMSA) was performed on nuclear extracts from un-
treated or IFN-L-treated HPB-ALL cells using a 32P-labeled
double-stranded oligonucleotide DNA probe corresponding
to the ISRE-like element of the RANTES gene promoter.
At least three IFN-L-inducible complexes (R1, R2 and R3)
were found associated with the RANTES ISRE-like oligonu-
cleotide probe (Fig. 4A, compare lanes 1 and 2). These com-
plexes appeared within 15 min of IFN-L stimulation, were still
present 2 h after stimulation, and decreased after 4 h (data not
shown). To assess the binding speci¢city of these complexes,
we next performed a DNA competition assay in the presence
of IFN-L. Addition of a 100-fold molar excess of unlabeled
oligonucleotides, used as competitors, displaced all of the
complexes. In contrast, a 100-fold excess of a mutated
ISRE-like oligonucleotide failed to displace the complex R1
(Fig. 4A, compare lanes 4 and 5), indicating that only this
Fig. 3. Implication of an ISRE-like element in the induction of
RANTES by type I IFNs. A: Site-directed mutagenesis of ISRE-
like element in the RANTES gene promoter. The number above the
sequence refers to the nucleotide position relative to the transcrip-
tion site of the RANTES gene promoter [17]. The boldface types
represent the nucleotide sequence for the ISRE-like element in the
RANTES gene promoter. Two mutants of the ISRE-like element
were obtained by oligonucleotide-directed mutagenesis: pmISRE1
and pmISRE2. The mutated sites are indicated. B: HPB-ALL cells
were transfected with the indicated plasmid (pRANTES,
pvRANTES, pmISRE1, or pmISRE2). Cells were then treated with
1000 U/ml of IFN-L, 24 h before the luciferase activity assay. The
relative luciferase activity was expressed as fold induction relative to
untreated cultures. Results are means þ S.D. of three independent
experiments.
Fig. 4. DNA binding activity in HPB-ALL cells treated with IFN-L.
A: HPB-ALL cells were untreated or treated with IFN-L (IFL) at
1000 U/ml, for 2 h before the preparation of nuclear extracts. A: 30
Wg of each nuclear extract was assayed for DNA binding activity by
EMSA with a 32P-labeled oligonucleotide from the ISRE-like ele-
ment from the RANTES gene promoter, in the presence or not of a
100-fold molecular excess of the unlabeled oligonucleotide probe
from wild-type ISRE-like element (R) or mISRE (mR) from
RANTES gene promoter. B: Competition assay using a 100-fold
molecular excess of the unlabeled GAS (Gas) oligonucleotides probe
from ISGF2 gene promoter. C: Identi¢cation of IFN-L-induced
ISRE binding complexes from the RANTES gene promoter.
D: Identi¢cation of IFN-L-induced ISRE binding complexes from
the ISG15 gene promoter. 30 Wg of nuclear extracts from untreated,
IFN-L-treated (1000 U/ml) HPB-ALL cells was incubated in the
presence of anti-Stat-1K, anti-Stat-2, anti-p48, or anti-IRF-1 anti-
bodies.
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complex is speci¢cally implicate in the RANTES ISRE-like
motif. Furthermore, as control, competition assay with an
unlabeled GAS oligonucleotide from ISGF2 [16] failed to dis-
place all of the complexes (Fig. 4B). In the presence of cyclo-
heximide, we observed that the complex R1 is only slightly
displace (Fig. 4A, lane 3), suggesting that the formation of the
complex R1 did not require de novo protein synthesis. Similar
results were obtained following treatment with IFN-K2 (data
not shown).
To further identify the nuclear factors involved in the for-
mation of the complexes on the ISRE-like element, antibodies
speci¢c of various members of the IRF and Stat protein fam-
ilies involved in IFN signaling were tested [1]. As shown in
Fig. 4B, antibodies speci¢c of Stat-2, ISGF3Q/p48 or IRF-1
failed to a¡ect the electrophoretic mobility of the complex R1.
Similar results were obtained with antibodies against Stat-3,
Stat-5, ICSBP or p300 (data not shown). In contrast the for-
mation of the complex R1 was speci¢cally inhibited by anti-
Stat-1-speci¢c antibody (Fig. 4B), demonstrating that Stat-1
binds to the RANTES oligoprobe in response to type I IFNs.
Of note, the pattern observed using the ISRE-like element of
RANTES was distinct from that observed using the classical
ISRE element of the ISG15 gene (Fig. 4C) [23]. These data
revealed that the activation of RANTES gene transcription by
type I IFNs is unlikely to implicate the classical ISRE/ISGF3
pathway.
Additional evidence for a non-classical pathway was ob-
tained using several mutant cell lines of the ISRE/ISGF3 sig-
naling pathway [24]. U1A, U2A, and U3A cells lacking func-
tional Tyk2, p48/ISGF3Q, and Stat-1, respectively, were
transiently transfected either with the p6-16 or the pRANTES
gene promoter constructs, and luciferase activity was deter-
mined after IFN-L treatment. In the parental cell line 2fTGH
transfected with either the p6-16 or pRANTES promoter con-
struct, treatment with IFN-L markedly induced promoter ac-
tivity (52- or 13-fold, respectively), as compared to untreated
cells (Fig. 5A). Similar induction of luciferase activity was
observed in p48-de¢cient U2A cells transfected either with
the pRANTES or pvRANTES constructs. In contrast, U2A
cells transfected by pmISRE1 and pmISRE2 failed to respond
to IFN-L (Fig. 5B). In line with the regulation of the p6-16
promoter by conventional ISGF3, the p6-16 construct was not
inducible in p48-de¢cient cells (Fig. 5A). This demonstrates
that p48/ISGF3Q transcription factor is not essential for the
response of RANTES gene promoter to IFN-L. In contrast,
both U1A and U3A cells transfected by the pRANTES pro-
moter construct failed to respond to IFN-L (Fig. 5A). These
data demonstrate that Stat-1 activation via a Tyk2-dependent
but p48/ISGF3Q-independent pathway is critical for induction
of RANTES gene promoter activity by the type I IFNs.
The results outlined in this study give evidence that
RANTES regulation in response to type I IFNs occurs at
the transcriptional level, and identify a novel IFN-responsive
element (ISRE-like) in the promoter region of RANTES. We
further identi¢ed the transcription factors required for the
ISRE-like binding activity. Supershift analysis demonstrated
that DNA^protein complexes contained Stat-1 protein, but
not Stat-2 or p48/ISGF3Q proteins. The signaling protein
Stat-1 is a key element activated by type I IFNs; several
results obtained in Stat-1-de¢cient mice demonstrated that
Stat-1 plays an obligate role in promoting most IFN-depen-
dent biologic responses [25,26]. Our data revealed that the
activation of RANTES gene transcription by type I IFNs is
unlikely to implicate the classical ISRE/ISGF3 pathway.
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